Daily Stock Analysis, DXCM, DexCom Inc, priceseries

DexCom Inc. Daily Stock Analysis
Stock Information
Open
117.78
Close
118.82
High
119.83
Low
116.23
Previous Close
118.03
Daily Price Gain
0.79
YTD High
156.16
YTD High Date
Feb 22, 2019
YTD Low
107.44
YTD Low Date
Apr 18, 2019
YTD Price Change
3.64
YTD Gain
3.16%
52 Week High
156.16
52 Week High Date
Feb 22, 2019
52 Week Low
72.60
52 Week Low Date
May 1, 2018
52 Week Price Change
45.09
52 Week Gain
61.16%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 10. 2017
67.04
Jan 30. 2017
78.81
13 Trading Days
17.55%
Link
LONG
Jun 12. 2017
71.68
Jun 27. 2017
75.27
11 Trading Days
5.01%
Link
LONG
Nov 2. 2017
47.72
Dec 11. 2017
58.62
26 Trading Days
22.85%
Link
LONG
Mar 20. 2018
65.59
Apr 6. 2018
70.29
12 Trading Days
7.17%
Link
LONG
May 2. 2018
74.31
Jun 7. 2018
89.89
25 Trading Days
20.97%
Link
LONG
Aug 16. 2018
128.31
Sep 14. 2018
141.98
20 Trading Days
10.66%
Link
LONG
Nov 6. 2018
132.92
Nov 14. 2018
140.00
6 Trading Days
5.32%
Link
LONG
Jan 7. 2019
129.95
Jan 24. 2019
144.39
12 Trading Days
11.11%
Link
Company Information
Stock Symbol
DXCM
Exchange
NasdaqGS
Company URL
http://www.dexcom.com
Company Phone
8582000200
CEO
Kevin Ronald Sayer
Headquarters
California
Business Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Laboratories & Research
CIK
0001093557
About

DexCom, Inc. is a medical device manufacturing company. The company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. Its products include Dexcom G4 PLATINUM System, Dexcom studio and Mobile apps. The company was founded by John F. Burd in May 1999 and is headquartered in San Diego, CA.

Description

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient's mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud-based reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management. The company also offers sensor augmented insulin pumps. It has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. The company was founded in 1999 and is headquartered in San Diego, California.